Green Tech ‘Prospect Generator’ in the Sights of this Investor

Source: Chris Temple   02/16/2022

Chris Temple of The National Investor explains why he has issued a speculative buy recommendation for BioLargo, a small-cap company with a flagship product that removes certain contaminants from water.

As I have learned ever more about this really unique “prospect generator” type of Green technology (and MUCH more) company, current big winner BacTech Environmental Corp. (BAC:CSE; BCCEF:OTC; OBT1:FRA) comes to mind. BAC is a company we patiently “suffered” with for a while until—now, in 2022—we are on the cusp of seeing pay dirt hit. In anticipation of that, BAC shares have appreciated several-fold in recent months especially.

BioLargo Inc. (BLGO:OTCQB) has far more irons in the fire, though, than does BacTech. What is similar now is that this company is likewise on the cusp of monetizing one or more of its numerous ideas/technologies/products.

For present purposes, I will defer to my colleague Penny Queen, who recently authored this outstanding deep dive into the company for Streetwise Reports.

Likewise, spend some time getting to know BioLargo at its own website.

Often times, a story will resonate with me because of my own life experiences and/or things I have seen myself. As I learned about BioLargo’s lead “candidate” for commercialization—its flagship product, the Aqueous Electrostatic Concentrator—I recalled what an environmental issue it’s been for years in my native upstate New York to have various chemicals discovered in ground water/aquifers.

The two biggies back then were chemicals that had been leaked by I.B.M. and Smith Corona into aquifers in the Endicott and Cortlandville areas, respectively. But all over America this same story has been repeated over the years.

Indeed, as BioLargo’s President/CEO Dennis Calvert reminded me (among many other things we discussed) in a couple lengthy conversations in recent days, the recent film Dark Waters gave a higher profile to this long-simmering environmental issue in the popular consciousness. Most everywhere there are all manner of industrial solvents and chemicals in water. These are compounds designed NOT to break down in nature, so they never leave.

BioLargo’s AEC system uses unique, proprietary technology to remove ONLY these PFAS (per- and polyfluoroalkyl substances) from water. The company recently announced that it had achieved success in removing PFAS to levels below federal standards in water of one major California municipality. By appearances, this was a major step on the way to more substantially monetizing this technology.

As Calvert explained to me, BLGO’s model of being somewhat a prospect generator able to have all its various irons in the fire (my term, in comparing for our purposes this company to those resource explorers out there who employ the same modus operandi) is enabled by a brain trust of about two dozen PhD’s, engineers and contracted experts. Ideally, where AEC and various other products/technologies are concerned (I’ll focus on a couple others in a follow-up to this), BioLargo will end up with one or more levels of income/cash-outs down the road, even as the majority of the money is provided by partners.

As I was marveling at (and I must confess, initially a bit overwhelmed by) all the moving parts here, Calvert quipped that BioLargo “is not a fly by,” meaning there is not one single, easy story. But, he continued, “The more you dig, the more you like it.”

Well, I dug more…and I do.

The significant number of opportunities to make some serious money down the road for a company with a mere $70 million or so market cap is a compelling story. And as you see in the above chart, more people are starting to warm up to it.

Technically, BLGO shares have become a little overbought in the last few weeks, in fact. But fundamentally, the story is so good here that, I.M.O., I wouldn’t wait to start building a position.

Though you should be mindful of the possibility that shares might pull back a little in the near term, I wouldn’t be too cute in trying/hoping to find a consolidation bottom. There are too many things here that could go right, as I will discuss further shortly.

So BioLargo is started as a BUY.

Don’t forget that you can follow my thoughts, focus and all pretty much daily ! ! !

* On Twitter, at https://twitter.com/NatInvestor

* On Facebook at https://www.facebook.com/TheNationalInvestor

* On Linked In at https://www.linkedin.com/in/chris-temple-1a482020/

* On my You Tube channel, at https://www.youtube.com/c/ChrisTemple (MAKE SURE TO SUBSCRIBE!)

Chris Temple, Editor/Publisher

Chris Temple is editor and publisher of The National Investor. He has had an over 40-year career now in the financial/investment industry. Temple is a sought-after guest on radio stations, podcasts, blogs and the like all across North America, as well as a sought-after speaker for organizations. His ability to help average investors unravel, understand and navigate today’s markets is unparalleled, and his ability to uncover “off-the-radar” companies is likewise. His commentaries and some of his recommendations have appeared in Barron’s, Forbes, CBS Marketwatch, Wall Street’s Best Investments/The Cabot Group, Kitco.com, the Korelin Economics Report, Benzinga.com, Palisade Radio, Mining Stocks Education, Mining Stock Daily and other media.

Disclosures

1) Chris Temple: I, or members of my immediate household or family, own securities of the following companies discussed in the broadcast: BacTech Environmental Corp. I personally am, or members of my immediate household or family are, paid by the following companies discussed in the broadcast: None. My company has a financial relationship with the following companies discussed in the broadcast: None. Chris Temple’s and The National Investor disclosures are listed below.

2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: BacTech Environmental Corp. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.

4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of BacTech Environmental Corp. and BioLargo Inc., companies mentioned in this article.

Additional disclosures

The National Investor is published and is e-mailed to subscribers from chris@nationalinvestor.com. The Editor/Publisher, Christopher L. Temple may be personally addressed at this address, or at our physical address, which is: National Investor Publishing, P.O. Box 1257, Saint Augustine, FL 32085. The Internet web site can be accessed at https://nationalinvestor.com/. Subscription Rates: $275 for 1 year, $475 for two years for “full service” membership (twice-monthly newsletter, Special Reports and between-issues e-mail alerts and commentaries.) Trial Rate: $75 for a one-time, 3-month full-service trial. Current sample may be obtained upon request (for first-time inquirers ONLY.) The information contained herein is conscientiously compiled and is correct and accurate to the best of the Editor’s knowledge. Commentary, opinion, suggestions and recommendations are of a general nature that are collectively deemed to be of potential interest and value to readers/investors. Opinions that are expressed herein are subject to change without notice, though our best efforts will be made to convey such changed opinions to then-current paid subscribers. We take due care to properly represent and to transcribe accurately any quotes, attributions or comments of others. No opinions or recommendations can be guaranteed. The Editor may have positions in some securities discussed. Subscribers are encouraged to investigate any situation or recommendation further before investing. The Editor receives no undisclosed kickbacks, fees, commissions, gratuities, honoraria or other emoluments from any companies, brokers or vendors discussed herein in exchange for his recommendation of them. All rights reserved. Copying or redistributing this proprietary information by any means without prior written permission is prohibited. No Offers being made to sell securities: within the above context, we, in part, make suggestions to readers/investors regarding markets, sectors, stocks and other financial investments. These are to be deemed informational in purpose. None of the content of this newsletter is to be considered as an offer to sell or a solicitation of an offer to buy any security. Readers/investors should be aware that the securities, investments and/or strategies mentioned herein, if any, contain varying degrees of risk for loss of principal. Investors are advised to seek the counsel of a competent financial adviser or other professional for utilizing these or any other investment strategies or purchasing or selling any securities mentioned. Chris Temple is not registered with the United States Securities and Exchange Commission (the “SEC”): as a “broker-dealer” under the Exchange Act, as an “investment adviser” under the Investment Advisers Act of 1940, or in any other capacity. He is also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.

Notice regarding forward-looking statements: certain statements and commentary in this publication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 or other applicable laws in the U.S. or Canada. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of a particular company or industry to be materially different from what may be suggested herein. We caution readers/investors that any forward-looking statements made herein are not guarantees of any future performance, and that actual results may differ materially from those in forward-looking statements made herein.

Copyright issues or unintentional/inadvertent infringement: In compiling information for this publication the Editor regularly uses, quotes or mentions research, graphics content or other material of others, whether supplied directly or indirectly. Additionally he makes use of the vast amount of such information available on the Internet or in the public domain. Proper care is exercised to not improperly use information protected by copyright, to use information without prior permission, to use information or work intended for a specific audience or to use others’ information or work of a proprietary nature that was not intended to be already publicly disseminated. If you believe that your work has been used or copied in such a manner as to represent a copyright infringement, please notify the Editor at the contact information above so that the situation can be promptly addressed and resolved.